Phase 3 trials are ongoing, and without completed large-scale safety and efficacy data, the compound cannot be considered ready for routine clinical use
It is dispensed in amber multidose vials containing 1,000 mcg/mL and compounded for use under either section 503A or 503B, allowing clinicians to individualize therapy for deficiency states ranging from pernicious anemia to postsurgical malabsorption
This 1000 mcg dose is the go-to for shots in the muscle or under the skin
Rather than directly supplying NAD+ precursors (like NMN or NR), it works by blocking an enzyme that consumes nicotinamide, theoretically preserving the substrate pool for endogenous NAD+ production
Third-Party Lab Tested All Peptides Costa Rica products are independently tested for purity, identity, and quality
This makes sure the treatment works well and keeps side effects low